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Abstract
Our aim is to study the behavior of memory Th cells (Th17,
Th17/1, and Th1 profiles) from early rheumatoid arthritis
(eRA) patients after their in vitro activation/expansion to
provide information about its contribution to RA chronicity.
Moreover, we analyzed the potential involvement of vasoac-
tive intestinal peptide (VIP) as an endogenous healing medi-
ator. CD4+CD45RO+ T cells from PBMCs of HD and eRA
were activated/expanded in vitro in the presence/absence of
VIP. FACS, ELISA, RT-PCR, and immunocytochemistry
analyses were performed. An increase in CCR6+/RORC+ cells
and in RORC-proliferating cells and a decrease in T-bet-
proliferating cells and T-bet+/RORC+ cells were shown in
eRA. mRNA expression of IL-17, IL-2, RORC, RORA,
STAT3, and Tbx21 and protein secretion of IL-17, IFNγ,
and GM-CSF were higher in eRA. VIP decreased the mRNA
expression of IL-22, IL-2, STAT3, Tbx21, IL-12Rβ2, IL-23R,
and IL-21R in HD and it decreased IL-21, IL-2, and STAT3 in
eRA. VIP decreased IL-22 and GM-CSF secretion and in-
creased IL-9 secretion in HD and it decreased IL-21 secretion
in eRA. VPAC2/VPAC1 ratio expression was increased in
eRA. All in all, memory Th cells from eRA patients show a
greater proportion of Th17 cells with a pathogenic Th17 and
Th17/1 profile compared to HD. VIP is able to modulate the
pathogenic profile, mostly in HD. Our results are promising
for therapy in the early stages of RA because they suggest that
targeting molecules involved in the pathogenic Th17, Th17/1,
and Th1 phenotypes and targeting VIP receptors could have a
therapeutic effect modulating these subsets.
Key messages
& Th17 cells are more important than Th1 in the contribution
to pathogenesis in eRA patients.
& Pathogenic Th17 and Th17/1 profile are abundant in
activated/expanded memory Th cells from eRA patients.
& VIP decreases the pathogenic Th17, Th1, and Th17/1
profiles, mainly in healthy donors.
& The expression of VIP receptors is reduced in eRA pa-
tients respect to healthy donors, whereas the ratio of
VPAC2/VPAC1 expression is higher.
Keywords Rheumatoid arthritis . Th17 . Th1 . Vasoactive
intestinal peptide . VPAC receptors
Introduction
Immune memory facilitates the maintenance of health by
preventing repeated infections but, if it becomes deregulated, it
can also lead to chronic inflammation. Rheumatoid arthritis (RA)
has been characterized by a Th1 response [1]. However, this
description has been modified with the discovery of a new Th
subset, Th17, which play a key role in inflammatory and autoim-
mune diseases, including RA [1]. Pro-inflammatory cytokine IL-
17 is the signature cytokine of Th17 cells, but can also be secreted
by non-immune cells [2]. Studies exploring the neutralization of
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IL-17 by antibodies or using IL-17-deficient mice showed that
this cytokine is involved in the autoimmune collagen-induced
arthritis (CIA) model [3]. In humans, existing studies suggest that
Th17 cells and their related cytokines play an important role in the
pathogenesis of RA and its number in peripheral blood is associ-
atedwith disease activity [4].Moreover, IL-17 levels are increased
in the synovial fluid of RA patients [5]. This cytokine, through its
specific receptors, is able tomodulate the function of other cells in
the joint such as fibroblast-like synoviocytes (FLS),macrophages,
chondrocytes, and osteoclasts [3, 5, 6]. Thereby, IL-17 is a key
orchestrator of RA chronicity. In addition to IL-17, other mole-
cules have been tested as markers of the occurrence of Th17 cells
in RA, such as the transcription factor RORC, the major lineage-
specifying transcription factors for Th17 subset development [7],
and the chemokine receptor CCR6, the characteristic Th17 hom-
ing receptor [8]. It has been described that in both peripheral blood
of healthy donors (HD) and synovial fluid of RA patients, all IL-
17-producing T cells expressing RORC were CCR6+ [9]. In
addition, other transcription factors are strongly associated with
the Th17 subset, such as RORA or STAT3 [1, 7].
Recent evidence suggests that Th17 cells may exhibit a
pathogenic or non-pathogenic phenotype according to their cy-
tokine secretion profile [10, 11]. Pathogenic Th17 cells secrete
IL-17, IL-21, IL-22, IL-2, IFNγ, and GM-CSF and non-
pathogenic Th17 cells secrete IL-17, IL-21, IL-9, and IL-10.
This heterogeneity of Th17 cells is barely known in human
RA. Moreover, epigenetic studies have shown that the Th17
subset is a less committed lineage when compared to Th1 and
Th2 cells [1]. Th17 cells are reported to exhibit a high degree of
phenotypic instability and plasticity, which enable them to ac-
quire a Th1-like phenotype [12]. In RA patients, a strong asso-
ciation between Th17 and Th1 subsets has been shown, being
also described the presence of a Th17/1 intermediate subset [13,
14], which belongs to the pathogenic Th17 phenotype.
As Th17 andTh1 are important in the pathogenesis of RA, the
study of the effect of microenvironment mediators could be
important to the design of therapies for their modulation. Vaso-
active intestinal peptide (VIP), one of the best-studied immuno-
modulatory neuropeptides [15, 16], is secreted by lymphocytes
and FLS in the joint [17]. VIP is involved in a broad range of
functions through its binding to its specific receptors, VPAC1 and
VPAC2 [18]. Healing effects of VIP in animal models of
inflammatory/autoimmune diseases, including a decrease of
Th1 and Th17 profiles, have been reported [15, 16, 19, 20]. In
vitro studies have shown that VIP induces Th17 differentiation
[21–23]. Specifically, it has been described that VIP prevents
arthritis in a CIA model through its anti-inflammatory and im-
munomodulatory actions [19]. There are also evidences for VIP
therapeutic effects in human RA [16, 17].
To date, studies on the involvement of Th17 and Th1 cells
in RA pathology have analyzed their presence in blood or in
synovial fluid of patients. However, little is known about the
behavior of memory Th cells after their in vitro activation/
expansion in early RA (eRA) that may provide information
about the involvement of these cells in RA chronicity. Our aim
is to examine, for the first time, in HD and in eRA patients the
resulting phenotype after 7 days of in vitro activation/
expansion of memory Th cells, analyzing both the Th17/1
and Th1 profiles and the specific profile and pathogenicity of
Th17 cells. Moreover, we examine the role of VIP in the
modulation of Th1, Th17/1, and Th17 phenotypes, studying
the involvement of its receptors.
Methods
Patients
Samples from 13 HD to 14 eRA patients were included in this
study. The study was performed according to the recommen-
dations of the Declaration of Helsinki and was approved by
the ethics committees of the Transfusion Center of
Comunidad Autónoma de Madrid (CAM) and La Princesa
and 12 de Octubre hospitals (Madrid). Only data from patients
fulfilling the 2010 ACR/EULAR criteria for eRA were col-
lected [24]. Blood samples were collected previous to treat-
ment prescription. HD were recruited from the Transfusion
Center. Following the Spanish Personal Data Protection law,
their demographic information was confidential. Among eRA
patients, there were 2 males and 12 females, 71.4 % tested
positive for ACPA, the mean age was 56.4±4.2 years (mean±
SD), and the mean DAS28 was 4.1±0.6 (mean±SD).
Isolation of human peripheral blood memory T cells
Memory Th cells were isolated from whole blood from HD
and eRA patients. For mononuclear cell isolation, density
gradient centrifugation by Ficoll–Hypaque (Sigma Aldrich)
was used. CD4+ T cells were isolated by negative selection
using a CD4+ T Cell Isolation Kit II (Miltenyi Biotec).
CD4+CD45RO+ T cells were then isolated by negative selec-
tion using CD45RA+ MicroBeads (Miltenyi Biotec). The
purity of CD4+CD45RO+ T cells was greater than 92 %.
In vitro expansion of human memory T cells
CD4+CD45RO+ T cells were cultured at 10×104 and at 5×104
cells/well (for HD and eRA patients, respectively) in RPMI-
1640-GlutaMAX media (Life Technologies, Carlsbad, CA,
USA) supplemented with 10 % fetal bovine serum (Lonza,
Basel, Switzerland) and 1 % penicillin/streptomycin (Life Tech-
nologies). Cells were activated/expanded with anti-CD3/anti-
CD28 coated beads (Life Technologies). CD4+CD45RO+ Tcells
were cultured in the absence or presence of 10nM of VIP
(Polypeptide group, Strasbourg, France) for both HD and eRA
patients.
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RNA extraction and semi-quantitative real-time PCR
For total RNA extraction we used the TriReagent method
(Sigma Aldrich, St. Louis, MO, USA). Two micrograms
RNA were reverse transcribed using a High Capacity cDNA
Reverse Transcription Kit (Life Technologies). Semi-
quantitative RT-PCR analysis for all molecules tested was
performed using TaqMan Gene Expression Master Mix (Life
Technologies), with the exception of IL-22, which was tested
using SYBR® Green PCR Master Mix (Life Technologies)
[24]. β-actin was used as an endogenous reference gene. We
normalized each sample with β-actin, using the formula
2−ΔΔCt. Amplification was performed in a 7900HT Fast
Real-Time PCR System apparatus (Applied Biosystems, Wal-
tham, MA, USA).
Determination of secreted cytokines by ELISA
Cells were restimulated on day 7 with 20 ng/ml phorbol
myristate acetate (PMA) and 0.5 μM ionomycin (Sigma Al-
drich) for 6 h. The levels of IL-17A, IL-21, IL-22, IFNγ, IL-9
(eBioscience, San Diego, CA, USA), and IL-10 (Diaclone,
Fig. 1 Th17 and Th1 phenotypes
of activated/expanded memory
Th cells from eRA patients and
healthy donors. T-bet and RORC
expression was determined by
flow cytometry analysis in
memory Th cells after activation/
expansion for 7 days. Auto-
fluorescence and isotype controls
were set up to determine the non-
specific fluorescence signal. a
Figure shows a representative dot
plot analysis indicating T-bet/
RORC expression. b–c
Figure shows the percentage of
total RORC positive cells, total T-
bet-positive cells. d Figure shows
the percentage of T-bet+/RORC−
cells, T-bet+/RORC+, and T-bet−/
RORC+ cells. Data are the mean±
SEM of three different cultures,
performed in triplicate.
Differences between RORC and
T-bet expression in
CD4+CD45RO+ T cells were
statistically significant,
δδδP<0.001. Differences between
CD4+CD45RO+T cells from HD
and eRA patients were
statistically significant, +P<0.05
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Madrid, Spain) in supernatants were analyzed by ELISA.
Final values were corrected considering the final volume
of the cultures and the number of viable cells in each
sample.
Flow cytometry analysis
After 7 days of culture, cells were collected and labeled with
phycoerythrin-conjugated CCR6 (clone 11A9, BD
Pharmingen, San Jose, CA, USA). Cells were then fixed and
permeabilized with Transcription Factor Buffer Set (BD
Pharmingen) according to the manufacturer’s specifications.
Next, cells were labeled with Alexa Fluor 488 conju-
gated T-bet (Clone O4 46, BD Pharmingen) ,
Allophycocyanin-conjugated RORC (clone AFKJS-9,
eBioscience), and Brilliant Violet 711-conjugated Ki67
(clone Ki-67, BioLegend, San Diego, CA, USA). Auto-
fluorescence and isotype controls were set up to define
non-specific fluorescence. Cytometric analysis was per-
formed using a LSR Fortesa flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA, using BD
FACSDiva software). Data analysis was performed
using FCS Express v3 (De Novo Software).
Immunocytochemistry staining
On day 7, cell suspensions were centrifuged onto glass slides,
dried, and fixed. After rehydration and blocking, cells were
incubated with 0.02 mg/mL rabbit anti-VPAC1 polyclonal anti-
body and mouse anti-VPAC2 monoclonal antibody (Acris Anti-
bodies, San Diego, CA, USA). Cells were then incubated with
1 μg/mL Alexa Fluor 488 donkey anti-rabbit IgG and Alexa
Fluor 594 goat anti-mouse IgG antibodies (Life Technologies)
and counterstained with 1 μg/ml Hoechst. Fluorescence was
examined on an Olympus BX51 microscope with DP72 camera
model (Olympus) and a Leica SP-2 AOBS confocal microscope
with inverted stand Leica DM IRE2 (Leica).
Statistical analysis
Samples were tested with a Normality test. A t-test was used to
compare different groups and correlations were conducted using
Pearson’s coefficient test. Both statistical tests were done using
GraphPad Prism version 4.0 software (GradphPad Software).
Results
Th17 and Th1 phenotypes in eRA patients versus HD
We analyzed the presence of Th17 (T-bet−/RORC+), Th1 (T-
bet+/RORC−), and Th17/1 (T-bet+/RORC+) cells by flow cy-
tometry after 7 days of in vitro activation/expansion of Th
cells from eRA patients and HD (Fig. 1). Results showed that
RORC+ cells were more abundant than T-bet+ cells in both
HD and eRA patients (Fig. 1b). Percentage of total RORC+
cells was higher, although not significantly, in eRA patients
than in HD, whereas the percentage of total T-bet+ cells was
lower (Fig. 1c). Percentage of T-bet+/RORC+ cells was sig-
nificantly lower in eRA patients (Fig. 1d).
Pathogenic Th17 phenotype in eRA patients versus HD
Given the high frequency of Th17 cells in both HD and eRA
patients we studied deeply their Th17 population. First, we
characterized the Th17 subset through the expression of
RORC and CCR6. Flow cytometric analysis of CCR6 and
RORC double-expressing cells showed a significant increase
in eRA (Fig. 2a). Then, we determined the cell proliferation by
analysis of Ki67 expression by flow cytometry in RORC-
expressing cells. As shown in Fig. 2b, eRA patients have a
slight increase of Ki67+RORC+ cells compared to HD. How-
ever, the percentage of Ki67+/T-bet+ cells were significantly
decreased in eRA patients. Next, we checked the secretion of
IL-17 and IL-21 in culture supernatants. Memory Th cells
from eRA patients showed significantly higher levels of IL-
17 (Fig. 2c). In addition, we characterized by RT-PCR the
expression of cytokines, transcription factors, and cytokine
receptors of the Th17 profile. IL-17A, RORC, RORA, and
STAT3 expression were higher in eRA patients, whereas IL-
23R was lower than in HD (Fig. 2d). Taken together, these
Fig. 2 Th17 profile of activated/expanded memory Th cells from eRA
patients and healthy donors. a CCR6 and RORC expression was
determined by flow cytometry analysis in memory Th cells after
activation/expansion for 7 days. Auto-fluorescence and isotype controls
were set up to determine the non-specific fluorescence signal. The figure
shows a representative dot plot analysis indicating CCR6/RORC
expression. The percentage of CCR6/RORC double-positive cells was
quantified. Data are themean±SEM of three different cultures, performed
in triplicate. b Ki67/RORC and Ki67/T-bet expression were determined
by flow cytometry analysis in memory Th cells after activation/expansion
for 7 days. Auto-fluorescence and isotype controls were set up to
determine the non-specific fluorescence signal. The figure shows two
representative dot plot analysis indicating Ki67/RORC and Ki67/T-bet
expression. Percentage of Ki67/RORC and Ki67/T-bet double-positive
cells was quantified. Data are the mean±SEM of three different cultures,
performed in triplicate. c Protein expression of IL-17A and IL-21 was
analyzed in culture supernatants by ELISA on day 7 of culture. Data are
the mean±SEM of eight different cultures, performed in duplicate. d
mRNA expression of cytokines (light grey), transcription factors (dark
grey), and cytokine receptors (black) was determined by real-time PCR in
activated/expanded memory Th cells on day 7 of culture, after PMA and
ionomycin stimulation. Data were analyzed normalizing with β-actin
mRNA expression and compared with the mRNA expression of
CD4+CD45RO+ T cells from HD. The fold change of each mRNA
expression with respect to different conditions is represented. Data are
the mean±SEM of eight different cultures performed in triplicate.
Differences between CD4+CD45RO+ T cells from HD and eRA
patients were statistically significant, +P<0.05, ++P<0.01, +++P<0.001
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results indicate that activated/expanded memory Th cells from
eRA patients are more committed towards the Th17 subset.
Next, we studied the pathogenic or non-pathogenic Th17
phenotype and the Th17/1 and Th1 profiles in eRA patients and
HD. Cells from eRA patients secreted higher levels of IFNγ
than HD (Fig. 3a). In addition, mRNA expression of IL-2 and
Tbx21 (gene encoding T-bet protein, the lineage-specifying
transcription factor for Th1) was higher in eRA patients
(Fig. 3b). On the other hand, the levels of cytokines associated
with a non-pathogenic phenotype IL-10 and IL-9 were slightly
decreased in eRA patients, although not significantly (Fig. 3c).
Together, these data indicate that activated/expanded memory
Th cells from eRA patients show a more pathogenic Th17 and
Th1 profile than memory Th cells from HD.
VIP modulation of pathogenic Th phenotype in eRA patients
versus HD
The presence of VIP during in vitro activation/expansion of
memory Th cells reduces the gene expression of not only
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cytokines, but also transcription factors and cytokine receptors
related to the Th17 subset and the pathogenic Th17/1 and Th1
phenotypes, with a greater intensity in HD than in eRA
patients (Fig. 4). First, we performed correlation studies be-
tween the mRNA expression of master regulators of both
Th17 and Th1 subsets. Results showed that, in memory Th
cells from HD, RORC was positively correlated with Tbx21,
while no correlation was observed in the presence of VIP
(Fig. 4a). mRNA expression analysis showed that VIP signif-
icantly decreased IL-22, IL-2, STAT3, Tbx21, IL-12Rβ2
(main IL-12 receptor subunit involved in Th1 differentiation),
IL-23R, and IL-21R in HD. However, VIP reduced IL-21, IL-
2, and STAT3 expression in eRA patients (Fig. 4b). Next, we
examined the effect of VIP on the secretion of several cyto-
kines. The presence of VIP decreased IL-22 and GM-CSF
levels in HD and IL-21 levels in eRA patients, whereas IL-9
was increased in HD (Table 1). Together, these data indicate
that the presence of VIP during expansion/activation of mem-
ory Th cells induces a shift towards a non-pathogenic Th17
profile and decreases the Th1 and Th17/1 phenotypes, mainly
in HD.
Expression of VIP receptors in memory Th cells in eRA
patients and HD
Although VPAC1 and VPAC2 receptors showed significantly
lower mRNA expression, the VPAC2/VPAC1 ratio was higher
in eRA patients (Fig. 5a). Additionally, we analyzed VPAC1
and VPAC2 protein expression in both HD and eRA patients
by immunocytochemical analysis. As shown in Fig. 5b, both
single stained (VPAC1 or VPAC2) and double-positive cells
were found in HD and eRA patients.
Discussion
To date, different studies have described the contribution of
Th1 and Th17 cells to RA chronicity by controlling numerous
cellular events [1, 3, 4, 25, 26]. However, these studies have
beenmostly performed in non-activated cells from fresh blood
of RA patients. The present study analyzed the pathogenic
Th17 and Th17/1 profile of memory Th cells after in vitro
activation/expansion during 7 days in eRA patients and com-
pared it to HD. Study in RA patients of recent onset allow to
reproduce in vitro what might occur in patients with eRA in
the active phase of the disease and avoid treatment
interferences.
Th17 and Th1 involvement in RA is well established;
however, it is less defined whether RA is mostly mediated
by Th17 or Th1 cells or whether each subset is important in a
different phase of the disease. Likewise, the presence of Th17
cells co-expresing IFNγ has been described in RA [13, 14].
Conversion of Th17 to Th1 phenotype might contribute to its
pathogenic potential. Thus, in our studies we have character-
ized the presence of Th17, Th1, and Th17/1 cells within
memory Th cells from eRA patients and compared it to HD
after in vitro activation/expansion for 7 days. Percentage of
RORC+ cells was higher than T-bet+ cells in both HD and
eRA patients, indicating that Th17 cells were more abundant
than Th1 cells. We further characterize the Th17 profile and
higher frequencies of double-positive CCR6 and RORC cells
were detected in eRA patients, in agreement with previous
observations [9]. The CCR6 expression in Th17 cells suggests
their ability to migrate to inflammatory sites [8] in response to
an inflammatory microenvironment through the interaction
with CCL20. Our proliferation studies on Th17 cells demon-
strated that double-positive Ki67 and RORC cells were slight-
ly increased in eRA patients. However, the percentage of
double-positive Ki67 and T-bet cells were significantly de-
creased in eRA patients, suggesting that Th17 cells are more
responsive than Th1 cells, in agreement with previous obser-
vations [9, 27]. This fact is further supported by the high
expression of IL-17 in eRA patients. Moreover, mRNA ex-
pression of the transcription factors RORC, RORA, and
STAT3 are higher in eRA patients. These results also suggest
the functional increase of the Th17 cells in eRA patients,
although their frequency in eRA patients is not significantly
increased. In this regard, although it has been described an
increased frequency of Th17 cells in peripheral blood of RA
patients [4, 27], other studies have not confirm this increase
[25]. Moreover, the hypothesis that the functional ability of
Th17 cells is more important than their percentage in periph-
eral blood has been suggested [28]. Overall, we have found a
stronger Th17 profile in activated/expanded memory Th cells
from eRA patients than in HD, which agrees with the previ-
ously described important role of Th17 in RA [1, 3, 5]. IL-17
promotes the survival and proliferation of FLS in RA patients
[6, 29] and in turn, FLS are able to control the pathogenicity of
Th17 by modulating IL-17R and IL-23 expression [6, 29].
This feedback-loop mechanism could contribute to the
synovium hyperplasia as well as to the inflammation in RA
patients.
Recent reports indicate the existence of two types of func-
tional Th17 cells depending on their cytokine secretion pro-
file, pathogenic (IL-17, IL-21, IL-22, IL-2, IFNγ, and GM-
CSF) and non-pathogenic cells (IL-17, IL-21, IL-9, and IL-10)
[10, 11]. In addition, Th17 subset is also characterized by its
phenotypic instability. Recent studies highlight the impor-
tance of their plasticity towards Th1 phenotype [12]. This
phenomenon is even more relevant in RA patients given the
implications of both subsets in the physiopathology of the
disease [13, 14] and it has been suggested as one cause for the
failure of therapies targeting Th17 cells [5]. Our results re-
ported that the percentage of total T-bet-positive cells was
lower in eRA patients. Given that the percentage of T-bet+/
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RORC− cells was similar in both HD and eRA patients, this
decrease in the T-bet percentage was due to the decrease in the
percentage of T-bet+/RORC+ cells. It has been described that
the frequency of IFNγ-producing CD4 T cells in peripheral
blood from RA patients was lower compared to HD [28].
Likewise, it has also been shown no differences in the per-
centage of IFNγ+IL17−, IFNγ+IL17+, and IFNγ−IL17+ in the
peripheral blood of RA patients compared to HD [25]. Other
authors have shown lower levels of Th17/1 cells in peripheral
blood suggesting that it is due to the increase of their recruit-
ment in the joint [13, 14]. On the other hand, results show a
strong pathogenic and related to Th1 profile phenotype in
eRA patients, showing higher levels of IFNу and GM-CSF
cytokines and lower levels of IL-10 and IL-9 cytokines. High
level of IL-2 and Tbx21 mRNA expression was also found in
eRA patients. The discrepancy between the percentage of T-
bet-expressing cells and the mRNA data related to T-bet
expression could be due to a more T-bet transcription individ-
ually, although a lesser percentage of total T-bet-positive cells.
On the other hand, this discrepancy could be also due to a
post-transcriptional modulation of this molecule, for example
by miRNAs or lcnRNAs. However, although lower T-bet-
expressing cells were detected in eRA cells, these levels are
sufficient to induce a greater IFNγ transcriptional response. In
summary, our results indicate that activated/expanded memo-
ry Th cells from eRA patients show stronger pathogenic Th17
and Th17/1 profiles than cells from HD.
An endogenous mediator able to mediate the Th17 subset
to a non-pathogenic phenotype and inhibit the Th17/1 and
Th1 profiles would be a good candidate as a therapeutic agent
in inflammatory diseases, specifically in RA. A recent study
reported that patients who were unable to increase VIP levels
in peripheral blood showed a worse clinical course despite
receiving more intense treatment [30]. It is known that VIP
modulates Th1, Th2, Th17, and Treg subsets [15, 16, 19, 23].
However, little is known about VIP modulation and VPAC
receptor expression in Th lymphocytes from RA patients. We
studied, for the first time, the effect of VIP on the Th17
heterogeneity and plastic profile of activated/expanded mem-
ory Th cells from eRA patients.
Regarding the Th17/1 and Th1 profiles, VIP reduced
the Th1 profile in HD, which agrees with previous
Fig. 3 Pathogenic Th17 and Th1 phenotypes of activated/expanded
memory Th cells from eRA patients and healthy donors. a Protein
expression of IFNу, IL-22, and GM-CSF was analyzed in culture
supernatants by ELISA after 7 days of expansion/activation of memory
Th cells and after PMA and ionomycin stimulation. Data are the mean±
SEM of eight different cultures, performed in duplicate. b IL-2 and Tbx21
mRNA expression was determined by RT-PCR on day 7 of culture after
PMA and ionomycin stimulation. Data were analyzed normalizing with
β-actin mRNA expression and compared with the mRNA expression of
CD4+CD45RO+ T cells from healthy donors. c Protein expression of IL-
10 and IL-9 was analyzed in culture supernatants by ELISA after 7 days
of expansion/activation of memory Th cells and after PMA and
ionomycin stimulation. Data are the mean±SEM of eight different
cultures, performed in duplicate. Differences between CD4+CD45RO+
T cells from HD and eRA patients were statistically significant, +P<0.05,
++P<0.01, +++P<0.001
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in vitro data in mouse and human cells [19, 21]. This
neuroimmunopeptide was able to reduce the expression
of two Th1 markers, Tbx21 and IL-12Rβ2, and to
induce a lack of correlation between RORC and
Tbx21 in HD. In addition, VIP down-regulated the gene
expression of several Th17 and Th1 markers and path-
ogenic indicators including IL-22, IL-2, STAT3, IL-23R,
and IL-21R in HD, but in eRA patients it only lowered
IL-21, IL-2, and STAT3 expression. VIP also reduced
IL-22 and GM-CSF production, as well as increased the
IL-9 secretion, favoring the non-pathogenic profile in
HD. IL-21 production was reduced in the presence of
VIP in eRA patients. IL-21 has been implicated in RA
[31] and blocking IL-21/IL-21R pathway showed an
amelioration of the disease in RA animal models [32].
Moreover, IL-21 is a central memory T cell-associated
cytokine that inhibits the generation of pathogenic Th1/
17 effector cells [33]. NFkB is an important transcrip-
tion factor for IL-21 [34] and VIP is able to reduce it in
several cells [19]. Ex vivo studies have previously dem-
onstrated the modulatory effect of VIP in RA [15–17].
In a pro-inflammatory milieu, VIP induced the down-
regulat ion of IL-22-specif ic receptors in FLS,
Fig. 4 VIP modulation of pathogenic Th17 and Th1 phenotypes of
memory T cells from eRA patients and healthy donors. a Correlation
between mRNA expression of RORC and Tbx21 was determined using
Pearson’s coefficients tests. Data are the mean±SEM of eight different
cultures performed in triplicate. b mRNA expression of cytokines (light
grey), transcription factors (dark grey), and cytokine receptors (black)
was determined by real-time PCR in activated/expanded CD4+CD45RO+
T cells on day 7 of culture, after PMA and ionomycin stimulation. Data
were analyzed normalizing with β-actin mRNA expression and
compared with the mRNA expression of CD4+CD45RO+ T cells from
HD. The fold change of each mRNA expression with respect to different
conditions is represented. Data are the mean±SEM of eight different
cultures performed in triplicate. Differences between CD4+CD45RO+ T
cells cultured in the presence and the absence of VIP were statistically
significant, *P<0.05, **P<0.01, ***P<0.001
Table 1 Set of cytokines whose secretion is modified by VIP during
activation/expansion of memory Th cells
Healthy donors eRA patients
−VIP +VIP −VIP +VIP
IL-21 1.54±0.20 1.17±0.09 0.99±0.08 0.53±0.08***
IL-22 8.42±1.22 4.84±0.97* 6.54±0.93 6.25±1.16
GM-CSF 11.83±1.37 6.46±0.80* 9.73±1.51 7.57±1.38
IL-9 0.29±0.06 0.85±0.27* 0.19±0.03 0.28±0.08
Values are ng of cytokines/1.106 cells. Data are the mean±SEM of eight
different cultures, performed in duplicate. Differences between
CD4+CD45RO+ T cells cultured in the presence and the absence of
VIP were statistically significant, *P<0.05, ***P<0.001
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diminishing their potential to respond to pathogenic
Th17 cells [35]. Therefore, our results confirm the
VIP-mediated decrease in Th17 and Th1 cytokines re-
ported in several inflammatory/autoimmune disease
models [19, 21]. These VIP effects are mediated
through its VPAC receptors. We demonstrated that
VPAC1 and VPAC2 are expressed in activated/
expanded memory Th cells. In eRA patients, the expres-
sion of both receptors is reduced in respect to HD,
whereas the ratio of VPAC2/VPAC1 expression is higher.
It has also been described that the presence and func-
tion of VPAC2 predominates over VPAC1 in FLS from
RA patients [17]. This differential VIP receptor expres-
sion in eRA patients, and consequently different signal
transduction, could also be involved in the weak effect
of VIP their cells. Although, other explication of the
smaller effect of VIP in eRA patients could be the
differences in starting T cells, which are more patho-
genic and associated to Th1 and Th17 phenotype.
Overall, our results indicate that activated/expanded mem-
ory Th cells from eRA patients generate a greater proportion
of Th17 cells with a pathogenic Th17 and Th17/1 profile than
those from HD. VIP lowered this pathogenic profile, being
more important in HD. Findings presented here in RA patients
with an early phase of the disease are very interesting from a
therapeutic point of view and support that targeting molecules
involved in the generation of pathogenic Th17, Th17/1, and
Th1 phenotypes could have beneficial effects. Likewise,
targeting VIP receptors could have a therapeutic effect
through the reduction of these pathogenic subsets.
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